MedTrace Logo

HL-300 Ointment in Healthy Volunteers

NCT07684937 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-07-06

No results posted yet for this study

Summary

To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.

Conditions

Interventions

DRUG

HL-300

Number of Healthy Volunteers:4 (Treatment group: 3, Placebo\*: 1)

DRUG

HL-300

Number of Healthy Volunteers:8 (Treatment group: 6, Placebo: 2);Dosing Days:Day 1;

DRUG

HL-300

Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1

DRUG

HL-300

Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1-Day 7, BID;

Sponsors & Collaborators

  • Hangzhou Highlightll Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2024-11-25
Completion
2024-11-25

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07684937 on ClinicalTrials.gov